Nachrichten zur Pfizer Inc. Aktie

Why the Market Dipped But Pfizer (PFE) Gained Today

In the closing of the recent trading day, Pfizer (PFE) stood at $27.57, denoting a +1.06% move from the preceding…

The Iran War Could Make Your Next MRI More Expensive

In this week’s edition of InnovationRx, we look at a serial entrepreneur’s effort to build an FDA-approved AI doctor, Pfizer’s…

Pfizer Buy

NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Pfizer auf "Buy" mit einem Kursziel von 34…

Jefferies belässt Pfizer auf Buy - Ziel 34 Dollar

NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Pfizer auf "Buy" mit einem Kursziel von 34…

Pfizer Stock Is Doing Something It Hasnt Done Since 2022

Up until recently, the stock has been a chronic underperformer.…

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle…

Why Pfizer (PFE) Dipped More Than Broader Market Today

In the closing of the recent trading day, Pfizer (PFE) stood at $26.97, denoting a -1.61% move from the preceding…

Pfizer tells shareholders to reject mini-tender offer

…

PFE Talzenna Combo Shows Strong Efficacy in Wider Prostate Cancer Use

Pfizers Talzenna/Xtandi combo meets phase III goals, significantly delaying disease progression in HRR-mutated metastatic castration-sensitive prostate cancer patients.…

Pfizer vs Moderna: Which Pharma Stock Has More Upside?

They arent just "pandemic stocks."…

PLX: 2025 Full Year Results

By John Vandermosten, CFANYSE: PLXREAD THE FULL PLX RESEARCH REPORT2025 Financial and Operational ReviewProtalix BioTherapeutics, Inc. (NYSE: PLX) announced 2025…

Pfizer: Im Still Expecting A Massive Rebound

…

Pfizer Aktienanalyse: Outperformance-Potenzial durch defensive Qualitäten - HSBC hebt Kursziel an

Bad Marienberg (www.aktiencheck.de)???? Gesundheitswerte gefragt: HSBC bleibt bei Pfizer auf "buy" - Warum die Aktie jetzt interessant wirdDie Aktie von…

PFE vs BMY: Which Large Oncology Drugmaker Is a Better Pick Now?

Pfizer and Bristol Myers are racing to strengthen oncology portfolios through deals, new drugs and pipelines ??? investors are weighing…

OTC Markets Hosts Virtual Investor Presentation with Dr. Seth Lederman, Co-Founder, CEO, and Chairman of Tonix Pharmaceuticals, and David Bautz, PhD, Senior Analyst at Zacks SCR

NASDAQ: TNXPJohn Viglotti: Hello, and welcome to the Life Sciences Investor Forum. On behalf of OTC Markets and our co-host,…

Pfizer Aktie (Monatschart): Pullback als zweite Chance? Chartanalyse

Düsseldorf (www.aktiencheck.de) - Pfizer-Chartanalyse von HSBC Trinkaus & Burkhardt:Die Analysten von HSBC Trinkaus & Burkhardt nehmen die Aktie von Pfizer…

Nektar (NKTR) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.DATEThursday, March 12, 2026 at 5 p.m. ETCALL PARTICIPANTSPresident & Chief Executive Officer — Howard W.…

Pfizer (PFE) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Pfizer (PFE) closed the most recent trading day at $26.86, moving 1.61% from the previous trading session.…

Pfizer Neutral

ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Pfizer auf "Neutral" mit einem Kursziel von 25…

UBS belässt Pfizer auf Neutral - Ziel 25 Dollar

ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Pfizer auf "Neutral" mit einem Kursziel von 25…

Pfizers Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable?

The company incurred a loss in its most recent quarterly results.…

Hims & Hers shares soar premarket; Pfizer, Agilent Technologies slip

Hims & Hers shares soar premarket; Pfizer, Agilent Technologies slip…

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware…

China approves Pfizer GLP-1 drug for weight management

China has approved Pfizers GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the ?US drugmaker said…

Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound?

Pfizer (PFE) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…

Pfizers Quiet Cash Comeback

…

Pfizer Aktie: GLP-1-Pipeline überzeugt - Upgrade auf BUY!

New York (www.aktiencheck.de) - Pfizer-Aktienanalyse von Argus Research:Die Analysten von Argus haben die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN:…

OPKO Health (OPK) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.DateFeb. 26, 2026Call participantsChairman and Chief Executive Officer — Phillip FrostVice Chairman and President — Elias…

Top Research Reports for Meta, Netflix & Pfizer

Meta Platforms, Netflix and Pfizer lead fresh research as AI bets, bold 2030 goals and patent cliffs shape their outlooks.…

Anleihen: Hoffnung für Privatanleger: Aussicht auf größere Auswahl an Unternehmensanleihen

Die EU will die Regulierung von Unternehmensanleihen lockern. Dann könnten Privatanleger bestimmte Bonds von Konzernen wie Coca-Cola, Microsoft oder Pfizer…

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware…

Massive News: Pfizers 6% Dividend Could Be Safer Than You Think

Is Pfizers 6% yield a rare opportunity hiding in plain sight, or are investors overlooking a major risk that could…

Is Pfizer Stock an Underrated Healthcare Investment Play?

Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success.…

AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?

AZNs stronger growth outlook and 2030 revenue target may outshine PFEs yield and cheaper valuation.…

Pfizer Aktie: Bewertung attraktiv, aber Druck bleibt - Barclays bleibt skeptisch

London (www.aktiencheck.de) - Pfizer-Aktienanalyse von Barclays:Emily Field, Analystin von Barclays, stuft die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN: 852009,…

David gegen Goliath in der PTBS-Therapie: Emyria fordert mit MDMA Big-Pharma-Konzerne wie Pfizer und GSK heraus

Anzeige / Werbung Der globale Markt für die Behandlung der Posttraumatischen Belastungsstörung (PTBS) steht im Jahr 2026 vor einer Zäsur.…

Meet the 6.3% Yield Dividend Stock That Could Soar in 2026

Pfizers long-acting GLP-1 weight loss candidate could set the stage for a stock rally.…

Pfizer: Hold As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

…

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

Pfizer made one thing clear this week: Its officially back in the obesity race.…

Adaptive Biotech (ADPT) Earnings Call Transcript

Image source: The Motley Fool.DateFeb. 5, 2026 at 4:30 p.m. ETCall participantsChief Executive Officer — Chad RobinsChief Financial Officer —…

Novo Nordisk: Pfizer weight loss drug offers credible new competition

Pfizer’s monthly GLP-1 data prompts caution as new rival approaches Phase III Citi has reiterated its neutral stance on Novo…

Pfizer Neutral

NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Pfizer mit einem Kursziel von 26 US-Dollar…

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

The data on Pfizers GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without…

PLX: CHMP Delivers Positive Opinion

By John Vandermosten, CFANYSE:PLXREAD THE FULL PLX RESEARCH REPORTCHMP Positive Opinion for Elfabrio Four-Week DosingIn October 2025, Protalix BioTherapeutics, Inc.…

ANALYSE-FLASH: JPMorgan belässt Pfizer auf 'Neutral' - Ziel 30 Dollar

NEW YORK (dpa-AFX) - Die US-Bank JPMorgan hat die Einstufung für Pfizer auf "Neutral" mit…

Pfizer verdient 2025 weniger - Erste Studiendaten für Gewichtssenker

NEW YORK (dpa-AFX) - Wegen eines Milliardenverlusts im Schlussquartal hat der US-Pharmakonzern Pfizer im vergangenen…

Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.…

ANALYSE-FLASH: JPMorgan belässt Pfizer auf Neutral - Ziel 30 Dollar

NEW YORK (dpa-AFX) - Die US-Bank JPMorgan hat die Einstufung für Pfizer auf "Neutral" mit einem Kursziel von 30…

LGND: New Year Program Updates

By John Vandermosten, CFANASDAQ:LGNDREAD THE FULL LGND RESEARCH REPORTIn the wake of the December analyst day, Ligand Pharmaceuticals, Inc.’s (NASDAQ:LGND)…

Pfizer verdient 2025 weniger - Erste Studiendaten für Gewichtssenker

NEW YORK (dpa-AFX) - Wegen eines Milliardenverlusts im Schlussquartal hat der US-Pharmakonzern Pfizer im vergangenen Jahr weniger verdient. Unter…